Short DAPT Wins, Ultra-Short Fails 🚫1️⃣✅3️⃣ Stratified Strategy From HOST-BR

Dr RR Baliga's "Got Knowledge Doc" Podkast

Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

4d ago 3:49

MP4•Episode home

🫀 Personalizing DAPT: When "One Size Fits All" Fails 🕊️💊

The HOST-BR trial in The Lancet offers an important clinical lesson:

Bleeding risk should guide antiplatelet duration after PCI — not habit, not inertia.

🔍 Key insight

In ARC-HBR patients, 1-month DAPT was not non-inferior to 3 months
In non-HBR patients, 3-month DAPT was non-inferior to 12 months and reduced bleeding

🧠 Clinical takeaway

➡️ Ultra-short (1-mo) DAPT is risky in high-bleeding-risk patients

➡️ Short (3-mo) DAPT is safe and bleeding-sparing in lower-risk patients

🔧 Precision medicine in action:

Stratify → Tailor → Protect

📎 HOST-BR | The Lancet (2025)

A beautiful reminder that medicine advances when we match therapy to physiology — not the other way around.

🌟 "Do no harm" is evolving… now it means do no unnecessary bleeding.

#Cardiology #InterventionalCardiology #PrecisionMedicine #DAPT #PCI #BleedingRisk #Lancet

765 episodes